Mycophenolate Mofetil Hexal (Mycophenolate Mofetil)

• Mycophenolate Mofetil is employed in the management of immune‑mediated conditions, particularly those requiring suppression of lymphocyte activity.
• Kidney transplantation: prevents acute rejection and supports graft survival.
• Heart transplantation: reduces the risk of early rejection episodes.
• Liver transplantation: helps maintain graft function by inhibiting immune response.
• Lupus nephritis: treats renal involvement by dampening autoimmune inflammation.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blocks de novo guanosine nucleotide synthesis, a pathway essential for proliferating T and B lymphocytes, thereby suppressing their proliferation and reducing immune‑mediated graft rejection or autoimmunity.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects

• Nausea or vomiting.
• Diarrhea or abdominal discomfort.
• Headache.
• Tremor or mild dizziness.
• Increased susceptibility to mild infections.

Serious or Rare Side Effects

• Severe infections, including opportunistic pathogens.
• Bone‑marrow suppression leading to leukopenia or anemia.
• Hepatotoxicity with elevated liver enzymes.
• Increased risk of malignancies, especially lymphoproliferative disorders.
• Progressive multifocal leukoencephalopathy (PML).

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

• Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
• Assess renal function: adjust dose in patients with impaired clearance.
• Avoid in pregnancy: contraindicated (Category X) due to teratogenic risk.
• Use effective contraception: required for women of child‑bearing potential.
• Store at room temperature: keep in the original pack, protect from moisture.

Mycophenolate Mofetil can interact with several agents, altering its exposure or safety profile.

Major Interactions (Avoid)

• Cyclosporine: increases mycophenolate exposure, raising toxicity risk.
• Tacrolimus: may elevate mycophenolate levels, requiring close monitoring.
• Live vaccines: heightened infection risk; avoid concurrent use.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce oral absorption.
• Azathioprine: additive bone‑marrow suppression potential.
• Rifampin or other enzyme inducers: can lower mycophenolate concentrations.